Archive: 07/12/2017
Two years of extended anastrozole therapy proved as effective as five years in clinical trial
Postmenopausal women with hormone-receptor positive (HR-positive) breast cancer who took the aromatase inhibitor anastrozole for two years after an initial five years of adjuvant endocrine therapy received an equal benefit ...
Dec 7, 2017
Temporary ovarian suppression with hormone analog may preserve fertility during breast cancer chemotherapy
Meta-analysis of individual patient data from five randomized clinical trials provided a high level of evidence that treatment with a gonadotropin-releasing hormone analog (GnRHa) could safely and effectively protect ovarian ...
Dec 7, 2017
Acupuncture reduced joint pain caused by aromatase inhibitor treatment in a randomized, Phase III clinical trial
Acupuncture significantly reduced joint pain for postmenopausal women with early-stage breast cancer receiving treatment with an aromatase inhibitor compared with both sham acupuncture and no treatment, according to data ...
Dec 7, 2017